hyperlipidemias/obezite

Bağlantı panoya kaydedilir

Sıralama türünü seçin

Sayfa 1 itibaren 642 Sonuçlar

Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/004301, filed Jul. 31, 2009, which claims benefit of Korean Patent Applications 10-2008-0075659, filed Aug. 1, 2008, and 10-2009-0032463, filed

Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010. FIELD OF THE

Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing indole-3-carbinol derivative as active ingredient

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of PCT International Application PCT/KR2011/010161, filed Dec. 27, 2011, which claims priority from Korean Patent Application 10-2011-0010585, filed Feb. 7, 2011. TECHNICAL FIELD The

Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009. TECHNICAL FIELD The

Composition of wood ear, shiitake, hawthorn fruit, roselle, celery and fruit of chinese plum for treatment and/or prevention of hyperlipidemia, atherogenesis and obesity

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The invention provides a water extract of Yan-Sheng-Yin (YSY), a Chinese natural dietary supplement for health promotion, comprised entirely of natural foods and a preparation comprising the same. The invention also provides a method for treatment and/or prevention of

Composition for the treatment of obesity and hyperlipidemia

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO PRIOR APPLICATIONS This application claims the benefit of PCT International Application No. PCT/MX2005/000058, filed Jul. 18, 2005, which claims priority from Mexican Patent Application No. PA/a/2004/0010692, filed Oct. 28, 2004, the entire disclosures of which are incorporated by

Use of a statin compound as local drug for treating obesity, diabetes, hypertension and hyperlipemia

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to medicine technology, and more specifically, it relates to a new use of HMG-CoA reductase inhibitor (statins compound) locally used for prevention and treatment of diabetes, obesity, hypertension, hyperlipidemia, artheroslerosis, cardiovascular

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

This is a U.S. National Phase entry based on PCT/CN2013/001429 filed Nov. 22, 2013, which respectively claiming priority to Chinese patent application 20120512630.8 filed Nov. 23, 2012 and Chinese patent application 201310426327.0 filed Sep. 18, 2013. FIELD OF THE INVENTION The present invention

Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national phase, pursuant to 35 U.S.C. .sctn.371, of PCT international application Ser. No. PCT/KR2011/003007, filed Apr. 25, 2011, designation the United States and published in Korean on Dec. 15, 2011 as publication WO2011/155705.

Implantable electroacupuncture system and method for treating dyslipidemia and obesity

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND INFORMATION An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden,

Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The present invention relates to pyrrolidinone derivatives of the formula I ##STR00001## in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2a, R.sup.2b, R.sup.2c, X, Y.sup.1 and Y.sup.2 are defined as indicated below. The pyrrolidinone derivatives I are GPR119 modulators and useful for the prevention

Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority benefit to EP Application No. 17305189.7, filed Feb. 21, 2017, the disclosure of which is herein incorporated by reference in its entirety. DETAILED DESCRIPTION The present disclosure relates to compounds of formula

Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The present invention relates to isoindolinone compounds of the formula I ##STR00001## in which A, X, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, Y and Z are defined as indicated below. The isoindolinone compounds I are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity,

Implantable electroacupuncture system and method for treating dyslipidemia and obesity

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

11-.beta.-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase Type I (11.beta.-HSD-1 or HSD-1), and methods of treatment using such compounds. The compounds are useful for the treatment of diabetes, such as non-insulin dependent type 2 diabetes

Facebook sayfamıza katılın

Herbal & Natural Medicine

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

55 dilde çalışır
Bilim destekli bitkisel kürler
Görüntüye göre bitki tanıma
Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
Aramanızla ilgili bilimsel yayınları okuyun
Şifalı bitkileri etkilerine göre arayın
İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır